000 04297naa a22005897i 4500
001 UMUN-OA-20261005-MLS-024
003 local
005 20261005174903.0
006 m o d
007 cr||||||||||||
008 261005s2017 xx o u000 0 eng d
024 7 _a10.1007/s12325-017-0612-x
_2doi
035 _a(local)EuropePMC:PMC5656728
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aGilles Salles
_eauthor.
245 1 0 _aRituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. /
_cGilles Salles; Martin Barrett; Robin Foà [and others].
264 1 _a[Place of publication not identified] :
_b[publisher not identified],
_c2017.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aRituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue. Funding F. Hoffmann-La Roche Ltd., Basel, Switzerland.
540 _aCreative Commons Attribution-NonCommercial. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by-nc/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aSafety
650 4 _aMonoclonal antibody
650 4 _aCD20
650 4 _aTreatment outcome
650 4 _aFollicular Lymphoma
650 4 _aRituximab
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _ahematology
655 4 _aReview articles.
700 0 _aMartin Barrett
_eauthor.
700 0 _aRobin Foà
_eauthor.
700 0 _aJoerg Maurer
_eauthor.
700 0 _aSusan O'Brien
_eauthor.
700 0 _aNancy Valente
_eauthor.
700 0 _aMichael Wenger
_eauthor.
700 0 _aDavid G Maloney
_eauthor.
773 0 _tAdvances in therapy
_gVol. 34, no. 10, (2017), pages/article 2232-2273
_x0741-238X
856 4 0 _uhttps://europepmc.org/articles/PMC5656728
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC5656728
_qlocal
942 _n0
999 _c1166
_d1166